CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore Idorsia Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 31, 2025
Patent NumberGrant DateTitleTotal Oppositions
Sep 4, 2024Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)1

Top competitors of Idorsia Pharmaceuticals

List of top competitors of Idorsia Pharmaceuticals based on patent oppositions.